Pfizer Sees No Future In NicOx Glaucoma Candidate After Failure In Japanese Phase II Trial
This article was originally published in PharmAsia News
Executive Summary
NicOx and Pfizer reported more disappointing news related to their nitric-oxide donating prostaglandin analog candidate for glaucoma Aug. 25, noting the compound failed to meet its primary endpoint in a Japanese Phase II trial